A little more than three months since Elevation Pharmaceuticals boasted about the "gold standard" Phase IIb data generated by its nebulized LAMA product for COPD, Sunovion has stepped in to buy the company in a $430 million deal.
One of the big themes at BIO 2012 is the avowed commitment that developers are making to the open R&D movement, an effort to find ways to cooperate on a precompetitive basis.
Perhaps the most persistent trend in the drug business is one management would prefer to discuss only with analysts, and certainly not with the rank-and-file. Once again, a laundry list of pharma
Sunovion Pharmaceuticals broke some bad news to sales reps for its respiratory meds this holiday season. The company is consolidating its national respiratory sales organization, laying off a number
Sunovion Pharmaceuticals' new antipsychotic drug has hit drugstores, aiming to capture a share of the already crowded market. It's a branded drug in a class that now includes one leading